NOX to Present Clinical Data at COSA Annual Meeting
Filed with ASX · · 6 pages · English
Earlier from Noxopharm
- Appendix 4C - quarterly
- Change of Registry Address: Automic P/L - Sydney Office
- NOX Subsidiary Announces Important Drug Discovery
- NOX to support expanded LuPIN study
- Nyrada-Key progress with cholesterol-lowering drug candidate
Later from Noxopharm
- NOX announces Positive Data from CEP-1 Study of Veyonda
- DARRT-1 study advancing on basis of positive clinical data
- NOX Receives $3.26M Federal Govt R&D Rebate
- Principal Investigator Discusses LuPIN-1 Study
- Veyonda and Radiotherapy Delivers Clinical Benefits
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm